PCSK9 and atherosclerosis: PCSK9 loss-of-function mutation carriers exhibit reduced LDL-C levels and are protected against atherosclerotic cardiovascular diseases (ASCVD) (2), whereas PCSK9 gain-of-function mutation carriers present with familial hypercholesterolemia and are at high risk for ASCVD (3).